Prophylactic or therapeutic agents for allergic ophthalmic diseases or allergic nasal diseases, comprising tricyclic triazolobenzazepine derivative
View Patent ↗The present invention provides a pharmaceutical composition for use in the prophylaxis or treatment of allergic ophthalmic diseases or allergic nasal diseases, which comprises 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzazepine, 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to the present invention has few side effects, exerts strong prophylactic and therapeutic effects in the late phase exhibiting pharmaceutical resistance to conventional instillations, and can be used appropriately for topical applications.
1. A method for the treatment of allergic ophthalmic diseases or allergic nasal diseases, which comprises administering a therapeutically effective amount of 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzazepine or a pharmaceutically acceptable salt thereof to a mammal.
2. A method for the treatment of allergic ophthalmic diseases or allergic nasal diseases, which comprises administering a therapeutically effective amount of 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine or a pharmaceutically acceptable salt thereof to a mammal.
3. The method according to claim 1 , wherein the compound is administered by instillation.
4. The method according to claim 1 , wherein the compound is administered as nasal drops.
5. The method according to claim 1 , comprising administering an effective amount of a compound together with a pharmaceutically acceptable carrier.
6. The method according to claim 2 , wherein the compound is administered by instillation.
7. The method according to claim 2 , wherein the compound is administered as nasal drops.
8. The method according to claim 2 , comprising administering an effective amount of a compound together with a pharmaceutically acceptable carrier.
9. The method according to claim 3 , comprising administering an effective amount of a compound together with a pharmaceutically acceptable carrier.
10. The method according to claim 4 , comprising administering an effective amount of a compound together with a pharmaceutically acceptable carrier.